| Name | Title | Contact Details |
|---|---|---|
Phani Konduru |
Chief Digital and Technology Officer | Profile |
Gary Starnes |
VP, IT Governance | Profile |
Brian Barnes |
Executive Vice President and Chief Information Officer | Profile |
Ric Stuebs |
Chief Information Security Officer | Profile |
Center for Holistic Options Inc is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The New York Genome Center (NYGC) is at the forefront of transforming biomedical research and clinical care with the mission of saving lives. As a consortium of renowned academic, medical and industry leaders across the globe, NYGC focuses on translating genomic research into clinical solutions for serious disease. Our member organizations are united in this unprecedented collaboration of technology, science, and medicine. We implement advanced genomic research, and integrate our findings with world-class technologies and physician-scientists in order to help solve diseases. We harness the diversity of New York`s institutions and people to drive scientific discoveries that will vastly improve clinical care — ethically, equitably and urgently. We advocate and educate, sharing our findings with the global scientific, medical and thought leadership communities to broaden the reach of the New York Genome Center to help patients in every corner of the world. We create synergies through collaboration to continually innovate and advance our vision.
Greater Rochester Health Foundation is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Rochester, NY. To find more information about Greater Rochester Health Foundation, please visit www.thegrhf.org
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.
Ascend Group Partners is a vertically integrated cannabis cultivator, processor, and dispensary operator focused on the Massachusetts, Illinois, and Michigan markets. We seek to foster a robust and inclusive cannabis industry through a premium, unmatched customer-focused retail experience.